Incorporating Novel Data into Clinical Practice

The first abstract highlighted that new or worsening anemia within the first 12 weeks of ruxolitinib therapy was linked to a higher risk of mortality and a trend toward greater reductions in daily ruxolitinib dosing. Although dose adjustments were generally modest and spleen responses appeared similar, patients with baseline anemia or those who developed anemia during treatment experienced poorer overall survival.

The second abstract highlighted that In JAK inhibitor–naive patients with myelofibrosis, momelotinib (MMB) demonstrated higher rates of achieving or maintaining transfusion independence (TI) at week 24 compared with ruxolitinib (RUX), regardless of baseline erythropoietin (EPO) levels. No significant differences in TI rates were observed across baseline EPO subgroups with MMB, indicating that treatment benefit was consistent and not influenced by EPO levels.